Cyclosporin for the Prevention and Treatment of COVID-19 Disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150107020592N22

Enrollment

Registered

2020-05-25

Start date

2020-03-20

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. Coronavirus infection, unspecified

Interventions

Intervention group: patient under cyclosporin treatment: Patients who have acute respiratory failure due to covid-19 and do not respond to antiretroviral therapy due to the unknown nature of the disea

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: covid patients non-intubated payients Age between 18-80

Exclusion criteria

Exclusion criteria: Allergy to cyclosporin intubated patients

Design outcomes

Primary

Measure	Time frame
Improve oxygenation. Timepoint: 0,1,2,3,7after treatment with cyclosporin. Method of measurement: pulse oximeter.;Improve ct scan. Timepoint: seven day after cyclosporine treatment. Method of measurement: CT scan unit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammad Reza Hashemian

Shahid Beheshti University of Medical Sciences

iran.criticalcare@yahoo.com+98 912 111 9279

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026